Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed that on 20 October 2026 it repurchased 171,200 H shares on the Hong Kong Stock Exchange, spending HKD 0.57 million at prices between HKD 3.33 and HKD 3.36 per share. The volume-weighted average consideration was approximately HKD 3.34 per share.
Following the transaction, Weigao Group’s treasury share balance rose to 67.92 million shares, while the number of issued shares excluding treasury stock fell marginally by 0.0038 % to 4.45 billion. The company’s total issued share capital remains unchanged at 4.52 billion shares.
The buy-back was executed under the general mandate approved on 29 May 2026, which authorises repurchases of up to 446.46 million shares. Including the latest transaction, Weigao Group has repurchased 10.59 million shares to date, representing 2.37 % of the outstanding shares at the time the mandate was granted. All repurchased shares are being held in treasury; none have been cancelled.
In line with Hong Kong Listing Rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 20 November 2026. Management has confirmed that the repurchase complied with all relevant regulatory and corporate requirements.
Comments